These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16556036)

  • 1. Ibandronate: efficacy in the treatment of metastatic bone disease.
    Diel IJ
    Future Oncol; 2005 Oct; 1(5):593-607. PubMed ID: 16556036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of ibandronate in metastatic bone disease: review of clinical data.
    Bell R
    Oncologist; 2005; 10 Suppl 1():8-13. PubMed ID: 16264107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibandronate: its role in metastatic breast cancer.
    Cameron D; Fallon M; Diel I
    Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials.
    Tripathy D; Body JJ; Bergström B
    Clin Ther; 2004 Dec; 26(12):1947-59. PubMed ID: 15823760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical efficacy of the bisphosphonate ibandronate in cancer treatment.
    Bauss F; Bergström B
    Curr Clin Pharmacol; 2008 Jan; 3(1):1-10. PubMed ID: 18690873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
    Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal safety of ibandronate.
    Jackson GH
    Oncologist; 2005; 10 Suppl 1():14-8. PubMed ID: 16264108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
    Diel IJ; Kurth AH; Sittig HB; Meden H; Maasberg M; Sandermann A; Bergner R
    Support Care Cancer; 2010 Oct; 18(10):1305-12. PubMed ID: 20151162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer.
    Heras P; Karagiannis S; Kritikos K; Hatzopoulos A; Mitsibounas D
    Eur J Cancer Care (Engl); 2007 Nov; 16(6):539-42. PubMed ID: 17944770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials.
    Geng CJ; Liang Q; Zhong JH; Zhu M; Meng FY; Wu N; Liang R; Yuan BY
    BMJ Open; 2015 Jun; 5(6):e007258. PubMed ID: 26038356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain.
    Heras P; Hatzopoulos A; Heras V; Kritikos N; Karagiannis S; Kritikos K
    Am J Ther; 2011 Sep; 18(5):340-2. PubMed ID: 20634675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates for malignancy-related bone disease: current status, future developments.
    Body JJ
    Support Care Cancer; 2006 May; 14(5):408-18. PubMed ID: 16450087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of ibandronate in the daily oncological practice].
    Nagykálnai T
    Magy Onkol; 2006; 50(4):325-7. PubMed ID: 17216006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis and bisphosphonate treatment of skeletal events and bone pain in metastatic cancer: focus on ibandronate.
    Sittig HB
    Onkologie; 2012; 35(6):380-7. PubMed ID: 22722461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study.
    Mancini I; Dumon JC; Body JJ
    J Clin Oncol; 2004 Sep; 22(17):3587-92. PubMed ID: 15337809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibandronate in metastatic bone pain.
    Heidenreich A; Ohlmann C; Body JJ
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):67-72. PubMed ID: 15490379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing metastatic bone pain: the role of bisphosphonates.
    Gralow J; Tripathy D
    J Pain Symptom Manage; 2007 Apr; 33(4):462-72. PubMed ID: 17397707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of bone pain relief with ibandronate and other bisphosphonates in disorders of increased bone turnover.
    Ringe JD; Body JJ
    Clin Exp Rheumatol; 2007; 25(5):766-74. PubMed ID: 18078631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature.
    Meattini I; Bruni A; Scotti V; Livi L; De Luca Cardillo C; Galardi A; Cipressi S; Biti G
    J Chemother; 2010 Feb; 22(1):58-62. PubMed ID: 20227995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer.
    Diel IJ; Body JJ; Lichinitser MR; Kreuser ED; Dornoff W; Gorbunova VA; Budde M; Bergström B;
    Eur J Cancer; 2004 Jul; 40(11):1704-12. PubMed ID: 15251160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.